Shouping Xu Selected Research

Shouping Xu Research Topics

Disease

38	Neoplasms (Cancer) 04/2022 - 01/2010
26	Breast Neoplasms (Breast Cancer) 02/2022 - 11/2012
4	Neoplasm Metastasis (Metastasis) 04/2022 - 01/2021
4	Carcinogenesis 02/2022 - 02/2019
3	Triple Negative Breast Neoplasms 01/2021 - 10/2016
3	Head and Neck Neoplasms (Head and Neck Cancer) 04/2015 - 09/2010
2	Hypoxia (Hypoxemia) 01/2021 - 01/2018
2	Squamous Cell Carcinoma of Head and Neck 01/2021 - 04/2015
2	Nasopharyngeal Carcinoma 01/2021 - 05/2013
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2018
2	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 06/2016 - 09/2012
2	Endometrial Neoplasms (Endometrial Cancer) 11/2013 - 01/2010
1	Genomic Instability 01/2021
1	Xerostomia 01/2021
1	Radiation Pneumonitis 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Germinoma 06/2014
1	Male Breast Neoplasms (Male Breast Cancer) 11/2012

Drug/Important Bio-Agent (IBA)

12	Long Noncoding RNAIBA 01/2022 - 01/2015
7	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2017
6	Proteins (Proteins, Gene)FDA Link 02/2022 - 10/2016
5	Biological ProductsIBA 06/2021 - 01/2017
4	Biomarkers (Surrogate Marker)IBA 02/2022 - 10/2016
4	Messenger RNA (mRNA)IBA 11/2021 - 10/2016
3	Phenobarbital (Luminal)FDA Link 11/2021 - 01/2017
3	Competitive Endogenous RNAIBA 08/2021 - 01/2020
3	hydrogen sulfite (bisulfite)IBA 01/2021 - 01/2018
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 01/2018
2	Phospholipid Hydroperoxide Glutathione PeroxidaseIBA 01/2022 - 01/2020
2	Estrogen ReceptorsIBA 01/2022 - 12/2017
2	IronIBA 01/2022 - 01/2019
2	Hormones (Hormone)IBA 01/2022 - 11/2012
2	Indicators and Reagents (Reagents)IBA 11/2021 - 01/2021
2	Pharmaceutical PreparationsIBA 10/2021 - 01/2021
2	Cell-Free Nucleic AcidsIBA 08/2021 - 01/2021
2	N-methyladenosineIBA 06/2021 - 01/2021
2	6-methyladenineIBA 06/2021 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2017
2	ChromatinIBA 01/2021 - 10/2019
2	Therapeutic UsesIBA 10/2020 - 06/2014
2	trans-crotonin (CTN)IBA 06/2016 - 04/2015
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 04/2022
1	AntigensIBA 01/2022
1	human ERBB2 proteinIBA 01/2022
1	Glutathione (Reduced Glutathione)IBA 01/2022
1	Lipoxygenase (Lipoxygenase-1)IBA 01/2022
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2022
1	Superoxides (Superoxide)IBA 01/2022
1	UbiquinoneIBA 01/2022
1	Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA 12/2021
1	oxidized low density lipoproteinIBA 12/2021
1	ferrous sulfideIBA 10/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021
1	Free RadicalsIBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 08/2021
1	Small Nucleolar RNA (snoRNA)IBA 08/2021
1	Transfer RNA (tRNA)IBA 01/2021
1	Protein Kinase CIBA 01/2021
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2021
1	Complement C1q (C1q Complement)IBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Ribonucleases (Ribonuclease)IBA 01/2021
1	LigandsIBA 01/2021
1	Ephrin-A4 (Ephrin A4)IBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Miat long non-coding RNAIBA 01/2020
1	Immune Checkpoint ProteinsIBA 01/2020
1	histone H3 trimethyl Lys4IBA 01/2020
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	Complement System Proteins (Complement)IBA 12/2019
1	LuciferasesIBA 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	Transcription Factor AP-2IBA 01/2019
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2018
1	Cyclin D1IBA 12/2017
1	CateninsIBA 12/2017
1	bis(2,4-dinitrophenyl)carbonateIBA 07/2017
1	Histones (Histone)IBA 01/2017
1	ErbB Receptors (EGF Receptor)IBA 10/2016
1	Small Interfering RNA (siRNA)IBA 10/2016
1	Cell-Penetrating PeptidesIBA 10/2016
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 10/2016
1	Phosphotransferases (Kinase)IBA 01/2015
1	Tamoxifen FDA LinkGeneric 11/2012

Therapy/Procedure

14	Therapeutics 04/2022 - 11/2012
14	Radiotherapy 09/2021 - 01/2010
7	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021 - 01/2010
4	Immunotherapy 01/2022 - 01/2020
2	Neoadjuvant Therapy 01/2022 - 01/2021
2	Drug Therapy (Chemotherapy) 10/2021 - 09/2021
1	Lasers (Laser) 10/2021
1	Intravenous Injections 10/2021
1	Biological Therapy 09/2021
1	Oncolytic Virotherapy 09/2021
1	Induction Chemotherapy 01/2021
1	Microbubbles 10/2016
1	Craniospinal Irradiation 06/2014
1	Conformal Radiotherapy 01/2010